Global Hypoparathyroidism Treatment Market: Snapshot
The rare condition named
hypoparathyroidism involves the reduction in the activity parathyroid
glands. The most common way a patient can suffer from hypoparathyroidism
is after the parathyroid glands get removed or damaged during surgery.
It is a state of low parathyroid hormone secretion and can cause a
severe drop in calcium levels in the blood as well as high levels of
phosphorus in the blood. Symptoms for hypoparathyroidism range from mild
tingling in fingers, hands, or the mouth, to more serious and painful
muscle cramps. Very rare symptoms exhibited by patients include
convulsions and extreme muscle cramping of the whole body. The two forms
of hypoparathyroidism include the deficiency of PTH due to low
secretion, and PTH not being able to elicit a response from the bones
and kidneys.
Report Overview @ https://www.transparencymarketresearch.com/hypoparathyroidism-treatment-market.html
Hypoparathyroidism is a conditions when
parathyroid glands does not work properly for creation of hormone.
Hypoparathyroidism is caused by many reasons as some are like injury or
removal of parathyroid glands, DiGeorge syndrome a genetic disorder,
autoimmune disease, cancer radiation treatment, and by low magnesium
level. The function of parathyroid hormone is to regulate the level of
phosphorous and calcium in the blood. The Symptoms of hypoparathyroidism
occurs when the level of calcium is little in blood and the phosphorus
is high, due to which the human body show some sign which include muscle
spasm, hair loss, dry skin, numbness, and seizures. Hypoparathyroidism
occurs in both child and adults. If Hypoparathyroidism occurs in child
it show some sign as poor tooth development, vomiting, headaches and
mental disorders.
Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=22715
Hypoparathyroidism Treatment Market: Drivers and Restraints
Hypoparathyroidism treatment market is
estimated to be a big market over the forecast periods, as the current
population over the globe are suffering from hypoparathyroidism, For
instance, a report published by Endocrine Society in 2016, it was
60-8,000 patients in the U.S are suffering from hypoparathyroidism.
Players are coming with new technology advancement for the treatment of
hypoparathyroidism, For instance, in January 2015, Shire-NPS
Pharmaceuticals, Inc. got approval from a product used for treatment of
hypoparathyroidism name as NATPARA (parathyroid hormone) which is an
injection for subcutaneous use. Current market are having less players
which are working on hypoparathyroidism treatment. All the product in
hypoparathyroidism come under pharmaceutical or directly connect to
human, so it need to go under some clinical process and have to get the
approval from the respective agency before going to commercializes in
the market which is a restraints for the segment.
No comments:
Post a Comment